FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3010724304> ?p ?o ?g. }

• W3010724304 endingPage "1019" @default.
• W3010724304 startingPage "1013" @default.
• W3010724304 abstract "Patients with indolent conjunctival lymphomas exhibit good prognosis, with exceptional cases of dissemination, and are suitable candidates for intralesional therapies. We report the first prospective phase 2 trial using intralesional rituximab supplemented with autologous serum in adults with relapsed/refractory indolent CD20+ lymphoma of the conjunctiva (NCT01514344). Patients received 4 weekly intralesional injections of rituximab, followed by 6 monthly injections; 500 μL of autologous serum was added to rituximab in patients with lymphoma unresponsive to weekly doses. Safety, activity, and antitumor effect of autologous serum were investigated. Twenty patients with mucosa-associated lymphoid tissue (MALT)-type lymphoma were enrolled. Tolerability was excellent, with only 3 mild local reactions. After weekly injections, 11 patients achieved tumor regression, 8 had stable disease, and 1 experienced progressive disease; 9 patients received autologous serum, with response improvement in 4 cases (3 complete responses, 1 partial response). At the end of treatment, 12 patients achieved a complete remission, and 1 achieved a partial response, with an overall response rate of 65% (95% confidence interval, 45-85). At a median follow-up of 42 months (range, 10-78), 12 patients remain relapse free, with 5-year progression-free survival and time-to-next-treatment rates of 59% ± 11% and 69% ± 11%, respectively. Three patients with local relapse were retreated with intralesional rituximab and serum; 2 achieved a complete response that lasted 25+ and 38+ months. Thus, intralesional rituximab is a safe and active therapy in patients with relapsed conjunctival MALT lymphoma. The addition of autologous serum improves response in some cases. Retreatment of local relapses can result in a second durable remission." @default.
• W3010724304 created "2020-03-23" @default.
• W3010724304 creator A5002203533 @default.
• W3010724304 creator A5016760892 @default.
• W3010724304 creator A5019034145 @default.
• W3010724304 creator A5019077797 @default.
• W3010724304 creator A5022006811 @default.
• W3010724304 creator A5025899043 @default.
• W3010724304 creator A5036985315 @default.
• W3010724304 creator A5039006383 @default.
• W3010724304 creator A5050568632 @default.
• W3010724304 creator A5056541118 @default.
• W3010724304 creator A5058371862 @default.
• W3010724304 creator A5065530821 @default.
• W3010724304 creator A5072055837 @default.
• W3010724304 creator A5074294567 @default.
• W3010724304 creator A5086920822 @default.
• W3010724304 date "2020-03-17" @default.
• W3010724304 modified "2023-10-10" @default.
• W3010724304 title "Treatment of MALT lymphoma of the conjunctiva with intralesional rituximab supplemented with autologous serum" @default.
• W3010724304 cites W145313061 @default.
• W3010724304 cites W147398146 @default.
• W3010724304 cites W1596002476 @default.
• W3010724304 cites W1804760652 @default.
• W3010724304 cites W1968626722 @default.
• W3010724304 cites W1997247910 @default.
• W3010724304 cites W2012596256 @default.
• W3010724304 cites W2038128964 @default.
• W3010724304 cites W2045732883 @default.
• W3010724304 cites W2048725744 @default.
• W3010724304 cites W2057352448 @default.
• W3010724304 cites W2079007023 @default.
• W3010724304 cites W2083317445 @default.
• W3010724304 cites W2085251775 @default.
• W3010724304 cites W2087885595 @default.
• W3010724304 cites W2089056685 @default.
• W3010724304 cites W2089071510 @default.
• W3010724304 cites W2093748782 @default.
• W3010724304 cites W2095035604 @default.
• W3010724304 cites W2112387181 @default.
• W3010724304 cites W2130931506 @default.
• W3010724304 cites W2132280112 @default.
• W3010724304 cites W2133201432 @default.
• W3010724304 cites W2162022565 @default.
• W3010724304 cites W2165623211 @default.
• W3010724304 cites W2273517499 @default.
• W3010724304 cites W2278506512 @default.
• W3010724304 cites W2560458198 @default.
• W3010724304 cites W2562172305 @default.
• W3010724304 cites W2591579290 @default.
• W3010724304 cites W2625779040 @default.
• W3010724304 cites W2740988213 @default.
• W3010724304 cites W52193652 @default.
• W3010724304 cites W60759546 @default.
• W3010724304 doi "https://doi.org/10.1182/bloodadvances.2020001459" @default.
• W3010724304 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7094013" @default.
• W3010724304 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32182364" @default.
• W3010724304 hasPublicationYear "2020" @default.
• W3010724304 type Work @default.
• W3010724304 sameAs 3010724304 @default.
• W3010724304 citedByCount "9" @default.
• W3010724304 countsByYear W30107243042021 @default.
• W3010724304 countsByYear W30107243042022 @default.
• W3010724304 crossrefType "journal-article" @default.
• W3010724304 hasAuthorship W3010724304A5002203533 @default.
• W3010724304 hasAuthorship W3010724304A5016760892 @default.
• W3010724304 hasAuthorship W3010724304A5019034145 @default.
• W3010724304 hasAuthorship W3010724304A5019077797 @default.
• W3010724304 hasAuthorship W3010724304A5022006811 @default.
• W3010724304 hasAuthorship W3010724304A5025899043 @default.
• W3010724304 hasAuthorship W3010724304A5036985315 @default.
• W3010724304 hasAuthorship W3010724304A5039006383 @default.
• W3010724304 hasAuthorship W3010724304A5050568632 @default.
• W3010724304 hasAuthorship W3010724304A5056541118 @default.
• W3010724304 hasAuthorship W3010724304A5058371862 @default.
• W3010724304 hasAuthorship W3010724304A5065530821 @default.
• W3010724304 hasAuthorship W3010724304A5072055837 @default.
• W3010724304 hasAuthorship W3010724304A5074294567 @default.
• W3010724304 hasAuthorship W3010724304A5086920822 @default.
• W3010724304 hasBestOaLocation W30107243041 @default.
• W3010724304 hasConcept C121332964 @default.
• W3010724304 hasConcept C126322002 @default.
• W3010724304 hasConcept C141071460 @default.
• W3010724304 hasConcept C142424586 @default.
• W3010724304 hasConcept C18031839 @default.
• W3010724304 hasConcept C197934379 @default.
• W3010724304 hasConcept C2778375690 @default.
• W3010724304 hasConcept C2779338263 @default.
• W3010724304 hasConcept C2779526237 @default.
• W3010724304 hasConcept C2780653079 @default.
• W3010724304 hasConcept C71924100 @default.
• W3010724304 hasConcept C87355193 @default.
• W3010724304 hasConcept C90924648 @default.
• W3010724304 hasConceptScore W3010724304C121332964 @default.
• W3010724304 hasConceptScore W3010724304C126322002 @default.
• W3010724304 hasConceptScore W3010724304C141071460 @default.
• W3010724304 hasConceptScore W3010724304C142424586 @default.
• W3010724304 hasConceptScore W3010724304C18031839 @default.

• next